Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Lot Consistency Study of COVID-19 and Influenza Combination Vaccine

← catalyst calendar

NCT06482359

Sponsored by Novavax (industry) · NVAX — their whole pipeline →.

Phase
Phase 2/3
Status
Withdrawn
Study type
Interventional
Design
Randomized · Single · Prevention
Enrollment
0actual

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

It was decided to not move forward with the study.

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2025-02-01actualWhen the study began enrolling
Primary completion2025-11-16estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2026-05-17estimatedThe whole study's end, after follow-up
First posted2024-07-01actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-03-11actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • COVID-19
  • Influenza

Interventions

  • Biological: coformulated CIC Vaccine — also filed as SARS-CoV-2 rS, tNIV, Matrix-M adjuvant
  • Biological: Fluzone HD trivalent

Primary outcomes

what the primary-completion date above is the date OF
Numbers of participants with solicited local and systemic AEs.
measured 7 days post-vaccination]
Numbers of participants reporting Unsolicited AEs and medically attended adverse events (MAAEs).
measured 28 days post-vaccination.
Number of participants with MAAEs, SAEs, AESIs (including [PIMMCs] and myocarditis and/or pericarditis).
measured 6 months (approximately 182 days) post-vaccination.

Permalink · NVAX's whole pipeline · Catalyst calendar · Every registered study · What changed